most low-density lipoprotein cholesterol (LDL-C) lowering is obtained with the first 5 to 10 mg of statin. 9 Nonstatin therapies are available to lower LDL-C levels. Ezetimibe is not approved to prevent cardiovascular events, and data from the only outcomes trial with this drug indicate that the number needed to treat per year to prevent a cardiovascular event is 350. 10 Bile acid sequestrants are poorly tolerated at high doses because of gastrointestinal adverse effects, but these agents lower LDL-C levels synergistically with statins and can play a useful role at low doses. The newest class of drugs, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, has been shown to markedly lower LDL-C levels. Two of these monoclonal antibodies, evolocumab and alirocumab, were approved by the Food and Drug Administration in 2015 for use in addition to maximally tolerated statin therapy in adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C levels.
In this issue of JAMA, Nissen and colleagues 11 report the results of the GAUSS-3 trial, which used a rigorous protocol to investigate the use of the PCSK9 inhibitor evolocumab among patients with statin intolerance related to muscle-related adverse effects. The results are illuminating, but many unanswered questions remain.
In phase A of the trial, 491 patients with well-documented muscle-related adverse effects to 2 or more statins were randomized to receive either atorvastatin (20 mg daily) or placebo for 10 weeks, followed by a 2-week washout, followed by crossover to the alternate treatment for 10 weeks. Intolerable muscle-related symptoms developed in 209 patients (42.6%) while taking atorvastatin but not placebo, 130 (26.5%) while taking placebo but not atorvastatin, 48 (17.3%) while taking both treatments, and 85 (17.3%) while taking neither treatment. In phase B, 218 patients who had exhibited musclerelated adverse effects while taking atorvastatin but not while taking placebo, or who had experienced a 10-fold increase in creatine kinase level after statin administration, were randomized to receive ezetimibe (10 mg daily) (n = 73 patients) or evolocumab (420 mg monthly) (n = 145 patients). At 24 weeks, LDL-C levels were reduced by 16.7% (from 221.9 mg/dL at baseline to 181.5 mg/dL at 24 weeks) in the ezetimibe group and by 52.8% (from 218.8 mg/dL at baseline to 104.1 mg/dL at 24 weeks) in the evolocumab group (P < .001). This result is not surprising; indeed, similar results have been reported with evolocumab or alirocumab in statin-intolerant patients in 3 previous trials, although in this trial Nissen et al followed a precise protocol that identified patients who were truly statin intolerant. [12] [13] [14] Should statin-intolerant patients be treated with PCSK9 inhibitors such as evolocumab? There are several arguments against such an approach. First, PCSK9 inhibitors are not approved for this indication. Although preliminary results are encouraging 15 and large, long-term outcome trials are well under way, PCSK9 inhibitors have not yet been shown to reduce cardiovascular events. Second, one-fifth of the statinintolerant patients in GAUSS-3 still reported muscle-related adverse effects while taking evolocumab. 11 Third, a 1-year supply of either alirocumab or evolocumab currently costs approximately $14 000. 16 According to a recent analysis, using a "willingness-to-pay" threshold of $50 000 per qualityadjusted life-year gained, a PCSK9 inhibitor would need to cost $2600 per year to be worthwhile for a statin-intolerant patient with cardiovascular disease and an LDL-level of 70 mg/dL or greater. 16 Such a categorical financial analysis implies that PCSK9 inhibitors should not be used in any statin-intolerant patients, a conclusion that would be inappropriate. However, a patient at very high risk for a cardiovascular event with intolerable muscle symptoms while taking even a low statin dose should be considered as a candidate for this treatment. Less than 1% of all "statin-intolerant" patients might belong in this group at present. For other patients with statin intolerance, the appropriateness of the use of these agents is less clear.
The management of care for statin-intolerant patients can be frustrating and time-consuming for patients and for phy-sicians. Patients experience their current symptoms but often do not appreciate the cardiovascular events that statins are preventing. Physicians should persist at finding solutions that minimize their symptoms and maximize risk reduction.
The very long-term outcomes reported for early statin primary prevention trials 17,18 are impressive, perhaps even inspiring. The Anglo-Scandinavian Cardiac Outcomes Trial (AS-COT) randomized patients with hypertension and multiple risk factors to receive atorvastatin (10 mg daily) or to placebo and was stopped after a median follow-up of 3.3 years because of benefit. 17 Approximately 8 years later, 11 years after randomization, total mortality, cardiovascular mortality, and noncardiovascular mortality were all significantly reduced in patients who had been in the statin group. In the West of Scotland Coronary Prevention Study (WOSCOPS), pravastatin (40 mg daily) reduced cardiovascular events compared with placebo over 4.9 years of treatment; however, at 20-year follow-up, total and cardiovascular mortality, as well as hospitalizations, were significantly reduced for any coronary event by 18% (P = .002), for myocardial infarction by 24% (P = .01), and for heart failure by 35% (P = .002). 18 This legacy effect of statins is impressive. PCSK9 inhibitors are just starting out. Whether PCSK9 inhibitors will have the same impressive long-term outcomes will not be known for many years.
